retatrutide phase 3 triumph for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the registrational clinical trials - Giblin - 2026 - Diabetes, Obesity and Metabolism The data just dropped —

And consult your US physician about next steps for your weight management protocol

Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic infections

The study showed a 13% reduction in major adverse cardiovascular events (MACE), a composite endpoint for cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, in patients treated with liraglutide compared with placebo at a mean follow-up of 3.8 years (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.780.97) and a significant reduction in cardiovascular death (HR 0.78, 95% CI 0.660.93)

Equal mass means one calculation covers both peptides simultaneously

One of them involves your 60-day guarantee working when you need it

inclusion of more healthy options, changes to portion sizes etc.)